

ELITE PHARMACEUTICALS INC /DE/
Form SC 13D
May 13, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. _____)*

Elite Pharmaceuticals, Inc.
(name of issuer)

Common Stock
(title of class of securities)

28659T-20-0
(CUSIP number)

I. Wistar Morris, III
c/o Boenning & Scattergood, Inc.
4 Tower Bridge, Suite 200
200 Barr Harbor Drive
West Conshohocken, Pennsylvania 19428
610-832-5271

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 12, 2011
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box o.

Check the following box if a fee is being paid with the statement o. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7).

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D
 FILED BY I. WISTAR MORRIS, III REGARDING
 ELITE PHARMACEUTICALS, INC. COMMON STOCK

CUSIP
 No. 28659T200

Page 2 of 5 Pages

1. Name of reporting person I. Wistar Morris, III
 S.S. or IRS Identification No. of above person
2. Check the appropriate box if a member of a group* (a)
(b)
 N/A
3. SEC USE ONLY
4. Source of Funds* OO
5. Check box if disclosure of legal proceedings is required pursuant to items 2(d) or 2(E)
6. Citizenship of Place of Organization Pennsylvania, U.S.
- | | | |
|--|--|--|
| NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH | 7. Sole Voting Power 6,443,724
8. Shared Voting Power 492,923
9. Sole Dispositive Power 6,443,274
10. Shared Dispositive Power 10,266,815 | |
|--|--|--|
11. Aggregate Amount Beneficially Owned by Each Reporting Person 16,710,539
12. Check Box if the Aggregate amount in Row (11) Excludes Certain Shares*
13. Percent of Class Represented By Amount In Row 11 9.26%
14. Type of reporting Person* IN

page 3 of 5

SCHEDULE 13D
FILED BY I. WISTAR MORRIS, III REGARDING
ELITE PHARMACEUTICALS, INC. COMMON STOCK

ITEM 1. SECURITY AND ISSUER

This statement relates to the common stock of Elite Pharmaceuticals, Inc., (The "Company"). The Company's principal offices are located at 165 Ludlow Avenue, Northvale, NJ 07647.

ITEM 2. IDENTITY AND BACKGROUND

The name of the person filing this statement is I. Wistar Morris, III, an individual (the "reporting person"). The reporting person's business address is c/o Boenning and Scattergood, Inc., 4 Tower Bridge, Suite 200, 200 Barr Harbor Drive, West Conshohocken, Pennsylvania 19428. He has recently retired, but was employed as a registered representative with Boenning & Scattergood, Inc., a NASD registered broker-dealer.

During the last five years, the reporting person has not been convicted in a criminal proceeding. During the last five years, the reporting person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, as a result of which was or is subject to a judgment, decree final order enjoining future violation of, or prohibiting, or mandatory activities subject to federal or state securities laws of finding any violation with respect to such laws.

The reporting person is a United States citizen.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

This schedule 13D covers 16,710,539 shares beneficially owned by Morris individually and through his immediate family. Of the 16,710,539 shares beneficially owned by Morris individually and through his immediate family, 6,443,724 shares are held in nominee name for his benefit, 4,933,646 shares are held in his wife's name, 4,840,246 shares are held in the name of a partnership for the benefit of his children, and 492,923 shares are held in the name of a Foundation in which Morris is co-trustee. The stock beneficially owned by Morris individually and through his immediate family was originally purchased as Preferred D shares, with personal funds beginning in 2007 with the last purchase being made in 2008. All their Preferred D shares were converted to common stock on April 27, 2011. Between April 29, 2011 and May 13, 2011, Morris's IRA and the Cotswold Foundation sold 5,667,450 shares.

SCHEDULE 13D
FILED BY I. WISTAR MORRIS, III REGARDING
ELITE PHARMACEUTICALS, INC. COMMON STOCK

ITEM 4. PURPOSE OF TRANSACTION.

The purpose of this filing is to report the sale of the stock beneficially owned by the reporting person and his immediate family since the conversion of their Series D shares to common stock on April 29, 2011.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

Morris individually and through his immediate family beneficially owns 16,710,539 shares of common stock of the Company. Based on the Company's 180,545,657 outstanding shares, represents approximately 9.26% of the outstanding common stock as of March 31, 2011. Filed as an Exhibit is a list of transactions done in Elite Pharmaceuticals, Inc. common shares since the filing of the previous 13D.

Morris has the sole voting power and the sole dispositive power over 6,443,724 shares held for his benefit in nominee name. He has no voting power, but shared dispositive power over 9,773,892 shares, of which 4,933,646 are in the name of his wife and 4,840,246 shares are in the name of a partnership for the benefit of his children. He has shared voting and shared dispositive power over 492,923 shares held in the name of a Foundation in which he is a co-trustee.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDING, OR RELATIONSHIP WITH RESPECT TO
SECURITIES OF THE ISSUER.

None.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Transaction Summary from 4/29/11 through 5/12/11, Item 5(c).

Signature.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

Date: May 13, 2011

I. Wistar Morris, III

SCHEDULE 13D
FILED BY I. WISTAR MORRIS, III REGARDING
ELITE PHARMACEUTICALS, INC. COMMON STOCK

Exhibit 1, Item 5(c)

Transaction Summary from 4/29/11 through 5/12/11

Tran Code	Security	Trade Date	Settle Date	Quantity	Avg. Price
I. Wistar Morris, III IRA					
sl	Elite Pharmaceuticals Inc	4/29/2011	5/4/2011	150,000	\$0.18
sl	Elite Pharmaceuticals Inc	5/2/2011	5/5/2011	440,000	\$0.17
The Cotswold Foundation Trust					
sl	Elite Pharmaceuticals Inc	5/3/2011	5/6/2011	850,000	\$0.15
sl	Elite Pharmaceuticals Inc	5/4/2011	5/9/2011	614,850	\$0.14
sl	Elite Pharmaceuticals Inc	5/5/2011	5/10/2011	663,000	\$0.14
sl	Elite Pharmaceuticals Inc	5/6/2011	5/11/2011	425,000	\$0.14
sl	Elite Pharmaceuticals Inc	5/9/2011	5/12/2011	520,200	\$0.14
sl	Elite Pharmaceuticals Inc	5/10/2011	5/13/2011	500,000	\$0.13
sl	Elite Pharmaceuticals Inc	5/11/2011	5/16/2011	654,400	\$0.12
sl	Elite Pharmaceuticals Inc	5/12/2011	5/17/2011	1,000,000	\$0.13